Download presentation

Presentation is loading. Please wait.

Published byGabriel Brennan Modified over 2 years ago

1
Using a Randomized Experiment to Measure the Impact of Firm Governance on Capital Raising and Investment Kate Litvak

2
Map of This Talk Original Goal Here: Do Precisely Nothing – Not really Identification Idea Theory Unexpected Difficulties and Solutions Results

3
Hierarchy of Identification Cross-Sectional Regs Firm Fixed Effects Exogenous Shock – Legal Change – Natural Disaster Randomized Trial – Gold Standard

4
Randomized Trial Here Conducted by the SEC in 2005-2007 Suspends Existing Restrictions on Short Selling Up to July 2007: – Rule 10a-1 from 1938 – Ok to Sell Short if Price Is Above immediately preceding sale, or At last sale price if it was higher than last diff price – Goal: Prevent Downward Price Spirals Restrictions Supported by Firm Managers – Claim: Short Sellers Opportunistic, Drive Down Prices

5
Trial Details True Randomized Experiment – Not Just Natural Experiment Based on Size etc. Take All Russell 3000 Firms (High Liquidity) – Rank by Trading Volume – Pick Every Third – “Pilot” Firms – Selection Period: June 2003-June 2004 Suspends Uptick Rule for Pilot Firms The Rest – Control Group Trial Period – May 2, 2005 to July 3, 2007

6
Prior/Concurrent Studies on Uptick Rule SEC Office of Economic Analysis (2007) – Effect of rule on volume of short sales, option trading, prices, liquidity, volatility Diether, Lee, Werner (2006) – Effect of rule on spread, volatility, short sale volume Alexander and Peterson (2006) – Volume, Volatility Around Announcement and Initiation Date of Pilot Program Bai (2007) – Effect on Price, Volatility, Volume During Mkt Stress Grullon et al. (2012) – Increase in Short Selling Causes Prices to Fall – Small Firms Reduce Equity Issues

7
Prior Studies on Uptick Rule No impact on – Daily Return Volatility – Liquidity – Magnitude and Speed of Price Decline – When Stocks Subject to Downward Pressure Caused by Earnings Shocks – Options Trading Weak Evidence: Overpricing Caused by Selling Restrictions So, SEC Concluded – Rule Useless – Repealed it in June 2007 Now, Adopted Different, Narrower Rule – No Trial There

8
Broad Research Question Interaction of Internal and External Governance Examples of Internal Governance – Boards, Procedures, S/h Voting Rules, Fiduciary Duties Standards Examples of External Governance – Share Price – Mkt for Corporate Control – Product Mkt Competition

9
Research Design Measures of Internal Governance + External Governance Outcome We Want: – Exogenous Shock to Some Form of Governance Then, See if Outcome Affected – Maybe Conditional of Internal Gov’ce Other Papers: – Shocks to Internal Governance Sarbanes-Oxley, Korean Corp Gov’ce Reform, DE Legal Rules This Paper: – Shock to External Governance

10
Identification Exogenous Shock to External Gov’ce – Through Randomized Trial

11
Hypothesis #1 Short Selling Permitted – Negative Opinions Incorporated into Stock Prices – Prices More Accurate – Investors More Willing to Invest – Cost of Capital Down – Capital Raising Up Prediction: – Short Selling Permitted Capital Raising Up Theory: – Lintner (1969), Miller (1977), Scheinkman and Xiong (2003), Gallmeyer and Hollifield (2006)

12
Hypothesis #2 Short Selling Permitted – Manipulators Run Down Prices – Panics Up – Stock Prices Artificially Deflated – Capital Raising Down Note: – Gov’ce Value of Short Selling Lower than Damage from Panics and Deflated Stock Prices Prediction: – Short Selling Permitted Capital Raising Down

13
Bottom Line on Hypotheses Testing Governance Value of Short Selling

14
Research Design (1) Classic Diffs in Diffs for Randomized Trials – Developed for Drug Trials Treated Firms – Exempt from restriction on short-selling Control Firms – Short-Selling Restricted Under Old Rule Compare: – Outcomes of Treated Firms v. Outcomes of Control Firms – During and Outside Test Period

15
Research Design (2) If Randomized Trial Perfectly Executed No Need for Regressions – Except if Want to Know Cross-Sectional Effects But Not Perfectly Executed Here – So, Need Some Extra Work Follow-Up – I Will Re-Do Prior Studies on Price, Volatility, Volume etc

16
Summary of My Findings (1) Short Selling Causes: – Increase in Equity Raising – No Change in Debt Raising – Increase in Capital Investment – Increase in R&D Investment – Increase in Dividend Payments

17
Summary of My Findings (2) What Kinds of Firms Most Responsive to Short Selling Effects? – Worse Internal Governance – Higher Prior Cash Flows

18
Summary of My Findings (3) What Does Not Predict Response? – Prior Financial Constraint Relevant for Cash Flow – Investment Sensitivity Literature – Evidence Consistent with KZ, not FHP Capital Raising Made Cheaper for Random Firms – Treated Firms generally responded by raising more $ And invested more – But more fin constrained firms not different from rest – Firs with higher pre-treatment cash flow investment sensitivity not different from rest

19
Data: Intended Randomization Firm Characteristic Treated Group, Mean Intended Control T-stat Treated v. Intended Control Number of Firms5801168 Asset Size2958.953245.280.67 Cash and Cash Equivalents19.9925.150.57 Capital Expenditures152.80141.140.59 Common Shares Issued110.78126.561.15 Long-Term Debt694.13769.530.74 Total Liabilities1772.772025.300.89 Total Dividends Paid41.1840.270.12 EBITDA396.77388.970.16 Number of Employees10.2611.310.80 PPE Total1829.851835.200.09 Sales Growth267.31295.380.56 R&D Expenditures54.8784.151.92 Trading Volume, in $6.10e+096.17e+090.10

20
But There is Category B… Created by SEC, Listed on their Page – Not self-selection – Principles of selection not reported Prior Papers Assumed: Inconsequential Rule for Them: – Exempted From Uptick Rule from 4pm to 8pm – So, Partially Treated! Check: – Random?

21
Data: Actual Assignment (Compliers) Firm Characteristic Treated Group, Mean True Control Group T-stat Treated v. True Control Number of Firms580781 Asset Size2958.95719.687.36 Cash and Cash Equivalents19.995.472.19 Capital Expenditures152.8037.307.19 Common Shares Issued110.7843.427.29 Long-Term Debt694.13204.836.25 Total Liabilities1772.77445.256.82 Total Dividends Paid41.185.376.36 EBITDA396.7779.808.38 Number of Employees10.263.906.47 PPE Total1829.85460.667.32 Sales Growth267.31261.550.11 R&D Expenditures54.8725.213.52 Trading Volume, in $6.10e+091.67e+098.78

22
Data: Actual Assignment (Non-Compliers) Firm Characteristic Treated Group, Mean Non-Compliers (Partially Treated) T-stat Treated v. Partially Control Number of Firms580387 Asset Size2958.958303.0415.84 Cash and Cash Equivalents19.9964.625.30 Capital Expenditures152.80349.3714.99 Common Shares Issued110.78293.0615.94 Long-Term Debt694.131897.4914.47 Total Liabilities1772.775185.4114.39 Total Dividends Paid41.18110.1812.04 EBITDA396.771009.7317.64 Number of Employees10.2626.0714.90 PPE Total1829.854646.1414.82 Sales Growth267.31362.321.56 R&D Expenditures54.87214.599.74 Trading Volume, in $6.10e+091.51e+1018.49

23
Kernel Density of Firm Asset Size for Treated v. Combination of Control and Partially-Treated Firms (Intended by Randomization) 0.0002.0004.0006.0008 Density 0200040006000800010000 at, Winsorized fraction.01 size, treated, as of 2004 size, intended control, as of 2004 kernel = epanechnikov, bandwidth = 171.1019 Kernel density estimate

24
Kernel Density of Firm Asset Size for Partially-Treated v. Control Firms (Compliers v. Noncompliers In Control Group)

25
So, Problem Non-Randomized Non-Compliance Cannot Compare Treated v. Intended Controls – Third of controls are partially treated Cannot Compare Treated v. Real Controls – Real controls not randomly chosen among intended controls

26
Solutions Developed by Statisticians for Randomized Trials – How to deal with non-compliers Inverse Propensity Weighting – Alone or with trimming of ranges without common support – Unbiased with heterogenous treatment effects – But inefficient Inverse Propensity Tilting – Creates exact covariate balance – Biased with heterogenous treatment effects – Unbiased with homogenous treatment effects – Efficient

27
Propensity score (p treated ) is “balancing score” (Rosenbaum & Rubin, 1983) – Same propensity same expected covariates Unbiased estimate with inverse propensity weights (IPW): Inverse propensity score reweighting

28
Short Version: Multiply [standard weights} * p * (1-p) Exact Covariate Balance Biased Estimate if Heterogenous Treatment Effects Inverse propensity tilt reweighting

29
Kernel Density of Propensity to be Treated for Treated v. Control Firms

30
Kernel Density of Propensity to be Treated for Partially-Treated v. Control Firms

31
Tests (1) Use Inverse Prop Tilting – Weighting to Produce Exact Covariate Balance Ask: – Do Treated Firms Raise More Capital During Treatment? Answer: – Yes for equity – No for debt

32
Panel, Inverse Prop Tilting Equity IssuanceDebt Issuance Treatment Period * Treated Firm 0.0285***-0.0109 (3.33)(-1.229) Treatment Period -0.0911***0.013 (-5.232)(0.85) Ln Assets -0.0877***0.0200*** (-16.27)(3.80) Ln Cash Holdings 0.0250***-0.00488*** (15.36)(-3.331) Ln Closing Price 0.0417***-0.0126** (7.28)(-2.233) Ln Trading Volume 0.0107***0.000555 (3.15)(0.16) Constant 0.252***-0.00583 (4.68)(-0.122) Fixed Effects firm, year Clusters firm Observations 8,3728,163 R-sq 0.2230.016 Firms 948

33
Tests (2) Use Inverse Prop Tilting – Weighting to Produce Exact Covariate Balance Ask: – Do Treated Firms Invest More During Treatment? Answer: – Yes for CapX – Yes for R&D – Also Increase Dividends

34
Panel, Inverse Prop Tilting Capital Expenditur R&D Expenditures Dividend Payments Treatment Period * Treated Firm 23.23***26.27***15.37*** (3.79)(2.92)(3.69) Treatment Period 9.247-14.09**-18.90*** (0.61)(-2.355)(-3.116) Ln Assets 22.21***30.99***-1.312 (4.63)(3.89)(-0.604) Ln Cash Holdings -0.4270.2550.654 (-0.354)(0.58)(1.27) Ln Closing Price -10.08**-13.68***-0.192 (-2.190)(-2.942)(-0.109) Ln Trading Volume 9.523***1.6891.566 (3.56)(0.73)(1.59) Constant -241.3***-131.7***17.67 (-5.306)(-3.307)(0.98) Fixed Effects firm, year Clusters firm Observations 8,4517,7558,500 R-sq 0.0690.1270.048 Firms 948939947

35
Tests (3) Use Inverse Prop Matching with Trimming – Covariate Balance not Exact – But not Biased when Heterogenous Treatment Effects – Censored, Uncensored, and No Weighting Ask: – Do Treated Firms Raise More Equity During Treatment? Answer: – Yes for equity

36
Panel, Inverse Propensity Matching Equity Issuance With weights, Censored With weights, Not Censored No Weights, Not Censored Treat Period * Treated Firm 0.0144**0.0184***0.0288*** (2.11)(3.05)(4.43) Treatment Period -0.0266***-0.0759***-0.0367*** (-3.523)(-5.977)(-4.854) Ln Assets -0.0887***-0.0800***-0.0844*** (-16.87)(-17.77)(-19.25) Ln Cash Holdings 0.0208***0.0186***0.0209*** (15.78)(16.47)(18.10) Ln Closing Price 0.0400***0.0317***0.0347*** (7.36)(6.97)(8.11) Ln Trading Volume 0.0112***0.0150***0.0155*** (3.64)(5.59)(6.08) Constant 0.211***0.163***0.115** (3.83)(3.90)(2.48) Fixed Effects firm, year Clusters firm Observations 9,56311,34612,316 R-squared 0.240.2070.21 Number of Firms 1,2311,2551,395

37
Tests (4) Use Inverse Prop Matching with Trimming – Covariate Balance not Exact – But not Biased when Heterogenous Treatment Effects – Censored, Uncensored, and No Weighting Ask: – Do Treated Firms Raise More Debt During Treatment? Answer: – No for debt

38
Panel, Inverse Propensity Matching Debt Issuance With weights, Censored With weights, Not Censored No Weights, Not Censored Treat Period * Treated Firm -0.0042-0.00688-0.0102 (-0.450)(-0.797)(-1.294) Treatment Period -0.0285*0.00459-0.00042 (-1.876)(0.33)(-0.0414) Ln Assets 0.0317***0.0217***0.0213*** (5.78)(4.69)(5.10) Ln Cash Holdings -0.00438***-0.00418***-0.00401*** (-3.045)(-3.093)(-3.306) Ln Closing Price -0.00584-0.00369-0.00453 (-1.084)(-0.719)(-1.006) Ln Trading Volume -0.00483-0.00266-0.00272 (-1.400)(-0.842)(-0.986) Constant 0.04480.03250.0371 (0.95)(0.74)(0.83) Fixed Effects firm, year Clusters firm Observations 9,18511,00812,041 R-squared 0.0170.0140.013 Number of Firms 1,2311,2551,396

39
Tests (4a) Cross-Sectional Results Ask: – What Predicts Whether Treated Firm Will Raise Capital During Treatment? Possible Candidates: – Pre-Treatment Financial Constraint Use Inverse Prop Matching with Trimming

40
Tests (4b) Intuition: – Firm Is Financially Constrained Pre-Treatment – Randomly Given Chance to Raise More Capital – It should take it! Ask: – Do Pre-Treatment Financial Constraints Cause Capital Raising During Treatment? Fin Constraint = Dividends/Net Income Use Inverse Prop Matching with Trimming Answer: – No – Very Robust – In All Specifications Panel, x-section Linear and Categorical Measures of Fin Constraint With different weighting, matching, etc.

41
Impact of Prior Fin Constraint on Equity Raising X-Section, Before-After Tests ΔEquityRaised /PPENT ΔEquityRaised /PPENT ΔEquityRaised /PPENT Inverse prop match weighted and trimmed yes Fin Constraint A in 2004 * Treated Firm0.0121 (0.37) Fin Constraint A in 2004-0.00956 (-0.562) Treated Firm-0.0167-0.01960.00974 (-1.097)(-1.334)(1.05) Fin Constraint B in 2004 * Treated Firm0.00909 (0.25) Fin Constraint B in 2004-0.00856 (-0.336) Fin Constraint C in 2004 * Treated Firm-0.0419 (-0.853) Fin Constraint C in 20040.0256 (0.63) Assets, Cash Holdings, Closing Price, Trading Volume Yes Constant0.01250.04210.0211 (0.12)(0.43)(0.27) Observations53752932 R-squared0.0590.0620.37

42
Impact of Prior Fin Constraint on Equity Raising Panel, Inverse Propensity Matching and Trimming ΔEquityRaised /PPENT ΔDebtRaised /PPENT Financial Constraint A * Treatment Group (0.00)0.00 (-0.127)(0.22) Financial Constraint A0.00(0.00) (0.08)(-0.202) Treatment Group(0.02) 0.01(0.00) 0.01 (-1.019) (1.05)(-0.472) (0.52) Financial Constraint B * Treatment Group (0.00)0.00 (-0.127)(0.22) Financial Constraint B0.00(0.00) (0.08)(-0.202) Financial Constraint C * Treatment Group(0.04)(0.05) (-0.853)(-0.633) Financial Constraint C0.03 (0.63)(0.52) Constant0.01 0.020.01 (0.10) (0.27)(1.05) (0.09) Assets, Cash Holdings, Closing Price, Trading Volumeyes Observations537.00 32.00490.00 27.00 R-squared0.06 0.370.01 0.11

43
More Robustness Same results with categorical measures of constraints

44
Tests (5a) Use Cash Flow – Investment Sensitivity as Proxy for Financial Constraint Theory: – Firm Cannot Raise Outside Capital – Has to Rely on Internal Cash Flows – Investment Correlated with Cash Flows

45
Tests (5b) Replicate Prior Results in FHP Ask: – Does Pre-Treatment Investment-Cash Flow Sensitivity Predict Pre-Treatment Financial Constraint? Fin Constraint = Dividends/Net Income No Treatment, Just Check Panel Use Inverse Prop Matching with Trimming Answer: – Yes – Higher Fin Constraint More Cash Flow – Investment Sensitivity

46
Correlation: Fin Constraint versus Cash Flow Investment Sensitivity (No Treatment) Panel, Inverse Prop Score Weighted and Trimmed Cash Flow Investment Sensitivity Financial Constraint Group 10.102*** (9.63) Financial Constraint Group 2-0.0362* (-1.872) Financial Constraint Group 3-0.109*** (-9.312) Constant0.213***0.288***0.309*** (23.96)(54.28)(56.02) Inverse prop match weighted and trimmedyes Obs863 R-Squared0.0970.0040.091

47
Tests (5c) Ask: – Does Pre-Treatment Investment-Cash Flow Sensitivity Cause Capital Raising During Treatment? – Firms Randomly Offered Easy Ways to Raise Capital Do High-Sensitivity Firms Raise More? Use Inverse Prop Matching with Trimming Answer: – No

48
Impact of Prior Investment Cash Flow Sensitivity on Equity Raising; X-Section, Before-After Tests Equity Raising Debt Raising Equity Raising Debt Raising Cash Flow Investment Sensitivity Pre-Tr * Treated Firm -0.106-0.0204*-0.109-0.0204* (-1.180)(-1.649)(-1.208)(-1.651) Fin Constraint Group 10.00517-0.00099 (0.29)(-0.412) Fin Constraint Group 20.02150.00127 (0.77)(0.35) Cash Flow Investment Sensitivity Pre- Treatment -0.0362-0.00192-0.0383-0.00146 (-0.532)(-0.216)(-0.558)(-0.162) Treated Firm 0.01590.004860.01540.00472 (0.54)(1.23)(0.53)(1.19) Assets, Cash Holdings, Closing Price, Trading Volumeyes Constant-0.05250.00618-0.05810.00599 (-0.556)(0.49)(-0.612)(0.47) Inverse prop match weighted and trimmedyes Observations486443486443 R-squared0.0520.0150.0530.016

49
Tests (6) Ask: – Doe Pre-Treatment Cash Flows Cause Capital Raising During Treatment? Use Inverse Prop Matching with Trimming Answer: – Yes – More Pre-Treatment Cash Flows More Capital Raising During Treatment All Adjusted for PPENT – Opposite of Theories Using Cash Flow Investment Sensitivity as Proxy for Fin Constraint

50
Impact of Prior Cash Flows on Equity Raising X-Section, Before-After Tests ΔEquityRaised /PPENT ΔDebtRaised /PPENT Cash Flows in 2004 * Treated Firm 0.0258***0.0009*** (9.80)(2.61) Treated Firm -0.021-0.00096 (-1.560)(-0.530) Assets, Cash Holdings, Closing Price, Trading Volume Yes Constant 0.06180.0149 (0.66)(1.18) Inverse prop match weighted and trimmed yes Observations 537490 R-squared 0.2030.02

51
Tests (7) Ask: – What Are Firms Doing with Extra Capital They Raise During Treatment Because of Treatment? Use Inverse Prop Matching with Trimming Answer: – Invest It

52
Impact of Equity Raising During Treatment on Investment X-Section, Before-After Tests ΔCapx /PPENT ΔCapx /PPENT ΔEquityRaised * Treated Firm 0.641** (2.52) ΔEquityRaised 0.221 (1.09) ΔDebtRaised * Treated Firm 6.637*** (2.99) ΔDebtRaised 0.0589 (0.04) Treated Firm 0.02990.00582 (0.69)(0.13) Assets, Cash Holdings, Closing Price, Trading Volume Yes Constant 0.264-0.00873 (0.88)(-0.0283) Inverse prop match weighted and trimmed yes Observations 537490 R-squared 0.1460.107

53
Tests (8) Ask: – Does Pre-Treatment Internal Gov’ce Affect Capital Raising During Treatment? Interaction of Internal and External Gov’ce Use Inverse Prop Matching with Trimming Answer: – Low-Gov’ce Firms More Equity Raising Substitute External Gov’ce for Internal – Firms with Higher Risk for Min S/hs More Equity Raising

54
Internal Governance Predicts Reaction to Changes in External Gov’ce, Panel, Inverse Prop Score Weighted and Trimmed Equity IssuanceDebt IssuanceEquity IssuanceDebt Issuance Yes BlockholdNo Blockhold Yes Blockholders No Blockholders E-Index Bad Gov E-Index Good Gov E-Index Bad Gov E-Index Good Gov Test Period * Control Group0.0277***-0.00881-0.00957-0.01760.0415***0.00908-0.0272**-0.0023 (2.78)(-0.642)(-0.955)(-0.830)(2.78)(0.89)(-2.060)(-0.190) Test Period-0.0477***-0.00552-0.005840.0531*-0.117***-0.0311***-0.00272-0.0227 (-4.290)(-0.357)(-0.412)(1.88)(-3.643)(-2.650)(-0.160)(-1.070) Assets, Cash Holdings, Closing Price, Trading Volume yes Constant0.214***0.1270.0399-0.1830.196**0.278***-0.09730.0655 (3.11)(0.93)(0.69)(-1.511)(2.10)(3.65)(-1.237)(0.88) Observations6,7431,7806,5161,7733,5684,9553,4834,806 R-squared0.2520.1520.0160.0460.2390.2270.0280.02 Number of gvkey780168780168526578523577

55
Other Internal Gov’ce Predictors of Responses to Changes in External Gov’ce Shareholder Votes to Amend Charter – Worse Gov’ce More Equity Raised Cumulative Voting – No Cumulative Voting More Equity Raised But Some RiskMetrics Measures Opposite So, Not Conclusive

56
Bottom Line Use Randomized Experiment Test Impact of Short Selling in Capital Raising and Investment Short Selling Permitted More Capital Raising More Investment No Evidence that Fin Constraints Affect Capital Raising and Affect Investment Some Evidence that External Gov’ce Is Substitute for Internal Gov’ce

57
Correlation: Fin Constraint versus Cash Flow Investment Sensitivity (No Treatment) Panel, Inverse Prop Score Weighted and Trimmed Cash Flow Investment Sensitivity Financial Constraint Group 10.102*** (9.63) Financial Constraint Group 2-0.0362* (-1.872) Financial Constraint Group 3-0.109*** (-9.312) Constant0.213***0.288***0.309*** (23.96)(54.28)(56.02) Inverse prop match weighted and trimmedyes Obs863 R-Squared0.0970.0040.091

Similar presentations

© 2017 SlidePlayer.com Inc.

All rights reserved.

Ads by Google